Pfizer has proposed to acquire Metsera, with Metsera confirming that definitive proxy statements regarding the transaction have been sent to its stockholders. The company also issued a statement responding to litigation filed by Pfizer, asserting its disagreement with the allegations and its intent to address them in the Delaware Court of Chancery. The proposed acquisition remains subject to customary closing conditions, including approval by Metsera stockholders and regulatory authorities. Metsera cautioned that there are substantial risks and uncertainties that could affect the outcome and timing of the transaction, including ongoing litigation and the possibility of competing offers.